Lv5
1100 积分 2025-05-23 加入
[Efficacy and safety of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with acute coronary syndrome without standard modifiable cardiovascular risk factors]
10小时前
已完结
Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
2天前
已关闭
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review
2天前
已完结
Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System
19天前
已完结
Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world
19天前
已完结
Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System
20天前
已完结
Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database
23天前
已关闭
Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab
24天前
已完结
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
25天前
已完结
皖公网安备34019202002308
